Ibodutant

{{Drugbox | Verifiedfields = changed | verifiedrevid = 444434892 | IUPAC_name = Nα-[(1-{[(6-methyl-1-benzothien-2-yl)carbonyl]amino}cyclopentyl)carbonyl]-N-{[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]methyl}-D-phenylalaninamide | image = Ibodutant_structure.svg | width = 150px

| tradename = | pregnancy_category = | legal_status = | routes_of_administration = Oral

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| IUPHAR_ligand = 2117 | CAS_number = | ATC_prefix = none | ATC_suffix = | ATC_supplemental = | PubChem = 11527495 | DrugBank_Ref =  ^Y | DrugBank = | UNII_Ref =  ^Y | UNII = 1H7RSQ28BJ | ChemSpiderID_Ref =  ^N | ChemSpiderID = 9702281 | StdInChI_Ref =  ^N | StdInChI = 1S/C37H48N4O4S/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31H,5-6,11-20,22,24-25H2,1H3,(H,38,42)(H,39,44)(H,40,43)/t31-/m1/s1 | StdInChIKey_Ref =  ^N | StdInChIKey = YQYSVMKCMIUCHY-WJOKGBTCSA-N

| chemical_formula = | C=37 | H=48 | N=4 | O=4 | S=1 | molecular_weight = 644.866 g/mol | smiles = CC1=CC2=C(C=C1)C=C(S2)C(=O)NC3(CCCC3)C(=O)NC(CC4=CC=CC=C4)C(=O)NCC5CCN(CC5)CC6CCOCC6 | synonyms = 6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4- yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide }}

Ibodutant is a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015, it is undergoing a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK₂, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe(the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study in women is ongoing.

See also

• GR-159,897
• Nepadutant
• Saredutant

References

• H. Spreitzer (May 26, 2008). "Neue Wirkstoffe - Ibodutant". Österreichische Apothekerzeitung (in German) (11/2008): 541.
• S. Giuliani, M. Altamura, C. A. Maggi. "Ibodutant. Tachykinin NK₂ receptor antagonist, Treatment of irritable bowel syndrome". Drugs of the Future. 33 (2): 111–115.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Template:Neuropeptidergics